SKU: 142362 Vueway 10 VL X 10 ML
Sales Unit: BX
Vueway (gadopiclenol) injection
485.1 mg/mL
10 mL vial (filled in 10 mL-vial) packed in a carton box of 10
(MFG. SKU 703042 NDC 0270-7030-42)
VUEWAY™ (gadopiclenol) solution for injection
Indications
VUEWAY Injection is indicated in adults and children aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in:
-
the central nervous system (brain, spine and surrounding tissues),
-
the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).
IMPORTANT SAFETY INFORMATION
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
-
The risk for NSF appears highest among patients with:
-
Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2), or
-
Acute kidney injury.
-
-
Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
-
For patients at highest risk for NSF, do not exceed the recommended VUEWAY dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.
Contraindications
VUEWAY Injection is contraindicated in patients with history of hypersensitivity reactions to VUEWAY.
Warnings
Risk of nephrogenic systemic fibrosis is increased in patients using GBCA agents that have impaired elimination of the drugs, with the highest risk in patients chronic, severe kidney disease as well as patients with acute kidney injury. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities.
Hypersensitivity reactions, including serious hypersensitivity reactions, could occur during use or shortly following VUEWAY administration. Assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders, administer VUEWAY only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, and observe patients for signs and symptoms of hypersensitivity reactions after administration.
Gadolinium retention can be for months or years in several organs after administration. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (brain, skin, kidney, liver and spleen). Minimize repetitive GBCA imaging studies, particularly closely spaced studies, when possible.
Acute kidney injury requiring dialysis has occurred with the use of GBCAs in patients with chronically reduced renal function. The risk of acute kidney injury may increase with increasing dose of the contrast agent.
Ensure catheter and venous patency before injecting as extravasation may occur, and cause tissue irritation.
VUEWAY may impair the visualization of lesions seen on non-contrast MRI. Therefore, caution should be exercised when VUEWAY MRI scans are interpreted without a companion non-contrast MRI scan.
The most common adverse reactions (incidence ≥ 0.5%) are injection site pain (0.7%), and headache (0.7%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for full Prescribing Information for VUEWAY Injection, including BOXED WARNING on Nephrogenic Systemic Fibrosis.
SKU | 142362 |
---|---|
MFR Number | 703042 |
Manufacturer | BRACCO/FORMERLY E-Z-EM |
UOM | BX |
Packaging | 10 Vials Per Box |